Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07109258

Effect of Dexamethasone on Labour Induction in Term Pregnancies

Status
Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

The aim of the study is to assess the effect of dexamethasone on labour induction in term pregnancies. Primary outcome: The interval between initiation of induction and beginning of the active phase of labour. Secondary outcomes: * Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation). * Duration of second stage of labour * Mode of delivery. * Fetal outcome. Group A: Will receive one dose of IM dexamethasone sodium phosphate 8 mg (2 mL). Group B: Will receive vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h. Group C: Will receive one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.

Detailed description

* Study type: Randomized Controlled Trial * Population of study: Pregnant women above 18 years of age, eligible for induction of labour. ● Study location: Cairo University Obstetrics \& Gynecology Hospital (Kasr Al-Ainy) * Methodology in details: * Every subject will be subjected to: * Written consent. * Complete history to exclude systemic disorders, congenital fetal malformation and contraindications for vaginal delivery. * General examination of the patients including pulse, blood pressure and body mass index, \[weight (kg)/ height (m2)\] (20-25) normal weight, (25-30) overweight, (30-35) obese, (35-40) very obese and \>40 morbid obese. * Abdominal examination including presentation, station of fetal head, fetal heart rate, uterine contractions and exclusion of multiple pregnancies. * Local examination to determine cervical dilatation at the beginning of intervention, presenting part, station of fetal head, pelvic adequacy and Bishop scoring. * Sonographic examination including assessment of fetal well-being by biophysical profile. * Patients will be randomly assigned to three groups using simple randomization via computer-generated random numbers will be used. * The women will be divided into three groups: 1. Group A: They will receive one dose of IM dexamethasone sodium phosphate 8 mg (2 mL). 2. Group B: They will receive vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h. 3. Group C: They will receive one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h. * Regarding group A,B and C the investigators will wait 24hrs after the last dose, then reassessment by senior obstetrician will be done and if induction is unsuccessful it'll be determined whether the patient is for either CS or second 24hr attempt at induction by misoprostol. * Primary outcome: The interval between initiation of induction and beginning of the active phase of labour. * Secondary outcomes: * Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation). * Duration of second stage of labour * Mode of delivery. * Fetal outcome. * Sample size Assuming that the mean interval between the start of induction and the beginning of the active phase among cases 2.87±1.57 hours versus 3.8±1.72 hours among controls, so a minimum sample of 150 patients, divided into three equal groups (50 patients each), will achieve 80% power at 0.05 significance level. Sample size calculated using OpenEpi, Version 3, open source calculator-(SSMean).

Conditions

Interventions

TypeNameDescription
DRUGDexamethasone (Decadron) 8mg IM injectionone dose of IM dexamethasone sodium phosphate 8 mg (2 mL) given at the start of labour induction
DRUGMisoprostol 25 mcgvaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.
DRUGBoth Misoprostol 25 mcg & Dexamethasone 8mg IM injectionone dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.

Timeline

Start date
2025-05-01
Primary completion
2025-09-01
Completion
2025-09-15
First posted
2025-08-07
Last updated
2025-08-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07109258. Inclusion in this directory is not an endorsement.